BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

978 related articles for article (PubMed ID: 31913198)

  • 1. miR-21 modulates cisplatin resistance of gastric cancer cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway.
    Gu Y; Fei Z; Zhu R
    Anticancer Drugs; 2020 Apr; 31(4):385-393. PubMed ID: 31913198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of microRNA-4295 enhances cisplatin-induced gastric cancer cell apoptosis through the EGFR/PI3K/Akt signaling pathway by targeting LRIG1.
    Yan R; Li K; Yuan DW; Wang HN; Zhang Y; Dang CX; Zhu K
    Int J Oncol; 2018 Dec; 53(6):2566-2578. PubMed ID: 30320337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a.
    Cheng C; Qin Y; Zhi Q; Wang J; Qin C
    Int J Biol Macromol; 2018 Feb; 107(Pt B):2620-2629. PubMed ID: 29080815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-95-3p serves as a contributor to cisplatin resistance in human gastric cancer cells by targeting EMP1/PI3K/AKT signaling.
    Ni Q; Zhang Y; Tao R; Li X; Zhu J
    Aging (Albany NY); 2021 Mar; 13(6):8665-8687. PubMed ID: 33714198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LDLR promotes autophagy-mediated cisplatin resistance in ovarian cancer associated with the PI3K/AKT/mTOR signaling pathway.
    Liu L; Sun YH; An R; Cheng RJ; Li N; Zheng JH
    Kaohsiung J Med Sci; 2023 Aug; 39(8):779-788. PubMed ID: 37218642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-181 regulates cisplatin-resistant non-small cell lung cancer via downregulation of autophagy through the PTEN/PI3K/AKT pathway.
    Liu J; Xing Y; Rong L
    Oncol Rep; 2018 Apr; 39(4):1631-1639. PubMed ID: 29484437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A; Li H; Li R; Lu L; Wu X
    Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2.
    Yang M; Shan X; Zhou X; Qiu T; Zhu W; Ding Y; Shu Y; Liu P
    Anticancer Agents Med Chem; 2014; 14(6):884-91. PubMed ID: 24875127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOXD1-AS1 regulates FOXD1 translation and promotes gastric cancer progression and chemoresistance by activating the PI3K/AKT/mTOR pathway.
    Wu Q; Ma J; Wei J; Meng W; Wang Y; Shi M
    Mol Oncol; 2021 Jan; 15(1):299-316. PubMed ID: 32460412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long Non-Coding RNA XLOC_006753 Promotes the Development of Multidrug Resistance in Gastric Cancer Cells Through the PI3K/AKT/mTOR Signaling Pathway.
    Zeng L; Liao Q; Zou Z; Wen Y; Wang J; Liu C; He Q; Weng N; Zeng J; Tang H; Fang R; Lei Z; Tang Z; Yang X; Cui S
    Cell Physiol Biochem; 2018; 51(3):1221-1236. PubMed ID: 30481766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lidocaine alleviates cisplatin resistance and inhibits migration of MGC-803/DDP cells through decreasing miR-10b.
    Zhang X; Gu G; Li X; Zhang C
    Cell Cycle; 2020 Oct; 19(19):2530-2537. PubMed ID: 32892697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-183 affects the development of gastric cancer by regulating autophagy via MALAT1-miR-183-SIRT1 axis and PI3K/AKT/mTOR signals.
    Li H; He C; Wang X; Wang H; Nan G; Fang L
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3163-3171. PubMed ID: 31352788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ethoxysanguinarine directly targets CIP2A to inhibit proliferation and induce autophagy of SGC7901/DDP cells].
    Wan F; Tan M; Xiang YC; Liu XW; Peng P; Liu Y
    Zhongguo Zhong Yao Za Zhi; 2022 Nov; 47(21):5890-5899. PubMed ID: 36472008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-let-7a regulates cell autophagy by targeting Rictor in gastric cancer cell lines MGC-803 and SGC-7901.
    Fan H; Jiang M; Li B; He Y; Huang C; Luo D; Xu H; Yang L; Zhou J
    Oncol Rep; 2018 Mar; 39(3):1207-1214. PubMed ID: 29328491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of CD133 Overcomes Cisplatin Resistance Through Inhibiting PI3K/AKT/mTOR Signaling Pathway and Autophagy in CD133-Positive Gastric Cancer Cells.
    Lu R; Zhao G; Yang Y; Jiang Z; Cai J; Hu H
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819864311. PubMed ID: 31405336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. microRNA-10b confers cisplatin resistance by activating AKT/mTOR/P70S6K signaling via targeting PPARγ in esophageal cancer.
    Wu K; Hu Y; Yan K; Qi Y; Zhang C; Zhu D; Liu D; Zhao S
    J Cell Physiol; 2020 Feb; 235(2):1247-1258. PubMed ID: 31267531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
    Gong T; Cui L; Wang H; Wang H; Han N
    J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway.
    Cao W; Yang W; Fan R; Li H; Jiang J; Geng M; Jin Y; Wu Y
    Tumour Biol; 2014 Feb; 35(2):1287-95. PubMed ID: 24068565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baicalein enhanced cisplatin sensitivity of gastric cancer cells by inducing cell apoptosis and autophagy via Akt/mTOR and Nrf2/Keap 1 pathway.
    Li P; Hu J; Shi B; Tie J
    Biochem Biophys Res Commun; 2020 Oct; 531(3):320-327. PubMed ID: 32800561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mir-20a-5p induced WTX deficiency promotes gastric cancer progressions through regulating PI3K/AKT signaling pathway.
    Li J; Ye D; Shen P; Liu X; Zhou P; Zhu G; Xu Y; Fu Y; Li X; Sun J; Xu J; Zhang Q
    J Exp Clin Cancer Res; 2020 Oct; 39(1):212. PubMed ID: 33032635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.